Champions Oncology (CSBR) Capital Leases (2018)

Champions Oncology (CSBR) posted quarterly Capital Leases of $95000.0 for Q4 2018, down 35.81% quarter-over-quarter from $148000.0 in Q3 2018.

Champions Oncology (CSBR) Capital Leases (2018) Analysis & Trends

Champions Oncology's Capital Leases history runs 1 years deep, the most recent figure standing at $95000.0 for Q4 2018.

In Q4 2018, Capital Leases changed N/A year-over-year to $95000.0; the TTM figure through Oct 2018 stood at $95000.0 (changed N/A YoY), while the FY2018 annual figure was $17000.0, changed N/A from the prior year.
Capital Leases for Q4 2018 stood at $95000.0, down from $148000.0 in the prior quarter.
The five-year high for Capital Leases was $148000.0 in Q3 2018, with the low at $17000.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Champions Oncology	68.61 Mn	68.61 Mn	7.03 Mn

Download Data